



Vasmed Technologies Limited

Unit 14, Kernick Industrial Estate
Kernick Road, Penryn, Cornwall
United Kingdom TR10 9EP
Tel : +44 (0) 788 068 4684
Fax : +44 (0) 845 515 4560
email: sales@vasmed.ae
www.vasmedtech.com

Vasmed Technologies Limited

Facility No. 116, Fujairah, Free Zone
Fujairah, United Arab Emirates
Tel.: +971 (0) 9 222 88 62
Fax: +971 (0) 9 222 88 63
email: sales@vasmed.ae
www.vasmed.ae





Avery label J8162, 63 (9.91 x 3.81 cm)

RAPSTROM

Sirolimus Eluting Cobalt Chromium Stent

Rapstrom Sirolimus Eluting Stent




Rapstrom benefits:

- Excellent trackability
- Improved conformity to suit vessel curvature
- Minimum stent recoil
- Hybrid stent design
- Proven clinical efficacy

Rapstrom Sirolimus Eluting Cobalt Chromium Coronary Stent system combines benefits of sirolimus drug to reduce restenosis and incorporate a fully biodegradable polymer that has the proven ability to reduce risk of thrombosis. Built on the Angstrom II Cobalt Chromium platform and the Vas Track stent delivery system, Rapstrom encompasses the unique hybrid stent design that facilitates trackability and usage with/through torturous anatomy. The strut thickness is maintained at the lowest dimension of 0.08 mm and along with the hybrid property of the stent, it allows for a very uniform expansion at the lesion with minimal metal-tissue surface area contact.


Angstrom II CoCr Stent System

Angstrom II Cobalt Chromium Coronary Stent platform provides a super thin alloy and thus with its minimal strut thickness, improved flexibility and excellent radial strength, it allows for one of the lowest profile coated stent available in the market. Vas Track high pressure, low profile stent delivery system is designed to reach and cross a stenosis with minimal effort. The unique CW hypotube design with the core wire running into the distal shaft allows for improved pushability and the balloon material provides optimal stent retention.




Compliance Chart

Diameter mm	4 atm	6 atm	8 atm	10 atm	12 atm	14 atm	16 atm	18 atm	20 atm
2.50	2.11	2.42	2.50	2.65	2.72	2.79	2.88	2.98	3.06
2.75	2.42	2.60	2.75	2.84	2.92	2.97	3.02	3.07	3.12
3.00	2.66	2.84	3.00	3.12	3.20	3.29	3.37	3.46	3.53
3.25	2.87	3.07	3.25	3.36	3.45	3.54	3.62	3.69	4.08
4.00	3.38	3.74	4.00	4.05	4.16	4.22	4.28	4.36	4.47
Nominal Pressure				Rated Burst Pressure					



Sirolimus stops the proliferation prior to G1 checkpoint and returns to G0 resting phase.



Size sheet

Diameter	2.5, 2.75, 3, 3.25, 3.5, 4.0 mm
Lengths	8, 13, 18, 23, 28, 33, 38 mm

Available in custom sizes and on OEM and OBL basis.

Sirolimus Drug

Sirolimus allows a dual mechanism that modulates inflammatory cell function and blocks smooth cell proliferation. The cytostatic properties of Sirolimus stops proliferation prior to G1 checkpoint returning cells to G0 resting phase. This prevents vessel damage and allows rapid and complete endothelialization, reducing risk of thrombosis.

Polymer and drug release

The PLLA - PGLA based polymer used for drug-binding is fully biodegradable within six months of implantation. These polymers are proven to reduce thrombus deposition by clear reduction of TAT (Thrombin - Antithrombin) and reduced platelet activation. Drug coating and release is affected through sirolimus crystals inserted into the base layer of the polymer for slow release and those on the surface protected with a top-coat provides the fast release. Fast release is completed within 5 days of constant release.

Technical Specifications

Stent Material	L605, Cobalt Chromium
Strut Width	0.08 mm
Radial Force	0.8 N/m
Profile before delivery	< 1 mm
Surface area	<30% based on expansion
Polymer	PLLA - PGLA
Balloon Material	Polyamide
Balloon Compliance	Low Compliance
Minimum Guiding Catheter	5 Fr.
Maximum Guidewire	0.014"